NYSE · PEN
Penumbra, Inc.
$318.73 +$0.83 (+0.26%) 1D After hoursKey Metrics
$12.50B
Market cap
73.10×
P/E · TTM
$1.45B
Revenue · TTM
$171.05M
Net income
EPS · TTM
$4.37
Dividend yield
—
Free cash flow
$212.73M
Beta · 1Y
0.12
EBITDA · TTM
$219.99M
Gross margin
67.4%
Snapshot
Market cap$12.50B
Enterprise value—
Shares outstanding39.3M
52-wk range$221.26 – $362.41
Avg volume · 20D410.0K
Net cash
—
Book value / share$37.63
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNYSE
About Penumbra, Inc.
IPO dateSep 18, 2015
Employees4700
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E73.10
P/S8.60
P/FCF58.78
EV/EBITDA—
EV/Sales—
Graham №$60.81
Profitability
Gross
67.4%
Operating
14.0%
Net
11.8%
FCF
14.6%
ROE / ROIC
13.0% · 19.9%
Financial Health
Current ratio6.02
Quick ratio3.95
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$1.06B
Cash Flow · TTM
Operating CF
$276.66M
Capex
−$63.93M
Free cash flow
$212.73M
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
6 / 9
Middling fundamentals · 6 of 9 signals passing
Altman Z-Score
19.7
Safe zone (> 2.99) · bankruptcy risk negligible
Graham Number vs Price
$60.81 vs $318.73
Trades 5.2× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings